PFE Value Scorecard - Pfizer

Value Scorecard · run 2026-10-18

13 value checks: 12 scored 1 to 5, plus moat evidence

33/60

low-moderate value score

Earnings & returns

EPS Trend

1/5

Diluted EPS: $5.47 (2022), $0.37 (2023), $1.41 (2024), $1.36 (2025). The latest figure is half the 2022 figure or less; the framework scores that as 1.

ROE Trend

2/5

ROE (net income / common equity): 32.8% (2022), 2.4% (2023), 9.1% (2024), 9.0% (2025). Median 9.0%, lowest 2.4%; the framework scores a median 5-10% as 2.

ROIC

2/5

ROIC of 6.0%: earnings before interest and taxes of $10.19B (pre-tax income $7.52B plus interest expense $2.67B; the 10-K's financial data has no standard operating income figure) divided by $171.18B of capital (total assets $208.16B minus current liabilities $36.98B), fiscal year to Dec 31, 2025, as filed in the 10-K (SEC EDGAR). The framework scores 5-10% as 2.

Profit Margins

3/5

Net margin of 6.8%; the framework scores 5-10% as 3; gross margin 74.7%, operating margin 27.9%.

Balance sheet & cash

Debt-to-Equity

4/5

Debt-to-equity of 0.74; the framework scores 0.3-0.8 as 4 (total debt $63.48B, total cash $11.70B).

Free Cash Flow

1/5

Free cash flow (operating cash flow minus capital expenditure): $26.03B (2022), $4.79B (2023), $9.84B (2024), $9.07B (2025). The latest figure is half the 2022 figure or less; the framework scores that as 1.

Retained Earnings

2/5

Retained earnings, as filed in the 10-Ks (SEC EDGAR): $125.66B (2022), $118.35B (2023), $116.72B (2024), $114.61B (2025). It ended at or below 2022; the framework scores that as 2.

Valuation models

Graham IV

4/5

IV = EPS x (8.5 + 2g) x (4.4 / Y) = $0.76 x (8.5 + 2 x 20.0) x (4.4 / 4.5) = $36.04 (EPS CAGR 91.7% capped at 20%). Current price $29.58; price is 17.9% below the model value.

DCF Value

4/5

FCF/share = $2.191, stage 1 growth = 2.5% for 5 years, terminal growth = 3%, discount rate = 10%. Stage 1 PV = $8.91, PV of terminal value = $22.64, DCF value = $31.55. Current price $29.58; price is 6.2% below the model value.

Margin of Safety

3/5

Graham value $36.04 (price is 17.9% below the model value); DCF value $31.55 (price is 6.2% below the model value).

Price-to-Book

3/5

P/B of 1.98; the framework scores 1.5-3.0 as 3.

Business quality

Moat Evidence

Not scored

A moat (a brand, a network, switching costs, patents, scale, a licence) is not a number in the filings, so Valerius doesn’t score it. Below are the figures and the words moat analysis starts from, from the company’s own 10-K filings. The conclusion is yours.

Return on capital, each year

Above 15% in 2 of 10 years (2016-2025); lowest 1.8%, highest 23.2%.

Gross margin, each year

Between 51.0% and 80.3% over 10 years (a range of 29.3 points).

Competition, in the company’s own words · 10-K filed Feb 26, 2026

Our business is conducted in intensely competitive and highly regulated markets. Many of our products face competition in the form of branded or generic drugs or biosimilars that treat similar diseases or indications. The principal forms of competition include efficacy, safety, tolerability, ease of use and cost. Though the means of competition vary among our products, demonstrating the value of our products is a

The opening of the company’s “COMPETITION” section in its 10-K, quoted word for word, not summarized or edited. It is the company’s own description, not Valerius’s view, and may include the company’s expectations. Open the filing.

Return on capital = operating income / (total assets − current liabilities), the ROIC row’s definition; 15% is the framework’s return threshold. For a year whose 10-K financial data has no standard operating income figure, earnings before interest and taxes (pre-tax income plus interest expense) is used. Gross margin = gross profit / revenue. Both from each year’s 10-K via SEC EDGAR. Moat analysis commonly looks at whether returns and margins held up over many years. These figures don’t say whether the company has an advantage, what it is, or whether it will last.

Capital Allocation

4/5

Capital allocation, 2022-2025: dividends or buybacks paid in every year (pass); $39.51B paid out against $49.73B of free cash flow (pass); total debt $34.86B to $63.96B, up 83.5%, 3.8x EBITDA (fail: up more than 10% and above 2x EBITDA); shares outstanding 5.62B to 5.69B, up 1.2% (pass). 3 of 4 tests passed; the framework scores that as 4.

Filings

Company notices to the SEC

Not scored

Three kinds of event the company reported to the SEC in the last 5 years, from its filings on SEC EDGAR.

These are events the company reported to the SEC. An auditor change or a late filing can have many causes; each date links to the filing, where the company explains it. Valerius does not score these.

How the Graham and DCF values were calculated

  Graham Formula:
    IV = EPS x (8.5 + 2g) x (4.4 / Y)
    EPS = $0.76, g = 20.0%, Y = 4.5
    g capped at 20.0% (3-year EPS CAGR was 91.7%)
    IV = $36.04
    Current price $29.58 vs Graham value $36.04 — price is 17.9% below the model value.

  DCF:
    FCF/share = $2.191
    Stage 1 growth = 2.5% for 5 years | terminal growth = 3.0% | discount rate = 10.0%
      Y1: $2.245 → PV $2.041
      Y2: $2.301 → PV $1.902
      Y3: $2.359 → PV $1.772
      Y4: $2.418 → PV $1.652
      Y5: $2.478 → PV $1.539
    Stage 1 PV sum = $8.91
    Terminal value at end of Y5 = $36.47
    PV of terminal value = $22.64
    DCF value = $31.55
    Current price $29.58 vs DCF value $31.55 — price is 6.2% below the model value.

Data from yfinance summary figures and financial statements, and from the company’s 10-K filings via SEC EDGAR; computed at a price of $29.58. Every score is calculated from the figures by the framework’s fixed rules, and the explanation beside it is generated from the same figures: Graham value, DCF value, margin of safety, ROIC, profit margins, debt-to-equity, price-to-book, EPS trend, ROE trend, free cash flow, retained earnings and capital allocation. No AI is involved in this scorecard. The moat is shown as evidence, without a score. Read each score with the figures beside it. Intrinsic value calculations are model outputs based on stated assumptions, not predictions.

Recent headlines · third-party publishers · not investment advice

In the news

Loading headlines...

The 8 newest headlines whose title names the company, shown automatically and never chosen by Valerius. From third-party publishers via Yahoo Finance, linked to the source. Valerius doesn't write or endorse them. Not investment advice.

PFE · Pfizer

PFE price